[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6177 followers
Created: 2025-07-26 08:21:09 UTC

Jagsonpal Pharma Reports Strong Q1 Growth 📈 | Revenue Up 23.1%, PAT More Than Doubles | MCap XXXXXXXX Cr

- XXXX% YoY revenue growth to ₹756 Mn in Q1FY26
- Operating EBITDA up XXXX% YoY to ₹157 Mn (20.8% margin)
- Net profit (PAT) more than doubled to ₹108 Mn (14.3% margin, +560 bps)
- Gross margins improved by XX bps to XXXX%
- Cash position strengthened to ₹1,609 Mn (+₹153 Mn in Q1)
- Ranked X in Gynae CVM segment
- 20+ brands in Top X of their categories (Gynaecology, Orthopaedics, Dermatology, Child-care)
- Asset-light model with 1000+ sales professionals
- Targeting 23%+ revenue growth for FY26

Complete Source:

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

Preview 👇 (First X out of XX pages)

![](https://pbs.twimg.com/media/GwxRLcaXsAASS8X.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1949022164872511764/c:line.svg)

**Related Topics**
[doubled](/topic/doubled)
[quarterly earnings](/topic/quarterly-earnings)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1949022164872511764)